Stay ahead with our updated market reports featuring the latest on tariffs, trade flows, and supply chain transformations.

What Is the Current and Projected Market Size of the HER2-Positive Breast Cancer Market Through 2034?

In the past few years, the market size for HER2-positive breast cancer has experienced robust growth. There’s a projection for this market to increase from $10.21 billion in 2024 to $10.96 billion in 2025, showing a compound annual growth rate (CAGR) of 7.34%. The past growth is attributed to factors such as the rise in early detection/diagnosis, increased awareness of HER2-positive subtypes, significant investments in R&D, the growing popularity of precision medicine, and amplified emphasis on enhancing patient outcomes.

In the coming years, the HER2-positive breast cancer market is anticipated to experience robust growth, escalating to $14.41 billion in 2029 with a compound annual growth rate (CAGR) of 7.08%. The projection period will see expansion due to factors such as the burgeoning requirement for liquid biopsy for non-invasive monitoring techniques, increased acceptance of various treatments utilized in combination, intensified attention on immunotherapies and innovative drug formulations, an escalated employment of liquid biopsy procedures for non-invasive monitoring, and the proliferation of dedicated cancer treatment facilities. The forecast period will also see major trends such as advancements in targeted therapies, innovative formulations, breakthroughs in immunotherapy methods, the emergence of novel HER2-focused therapies, and progress in biomarkers for improved patient stratification.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20832&type=smp

How Are Key Drivers in the Industry Acting as Catalysts for the Growth of the HER2-Positive Breast Cancer Market?

The increase in immunotherapy usage is predicted to fuel the expansion of the HER2-positive breast cancer market. Immunotherapy is a medical approach designed to boost or alter the body’s innate ability to combat various diseases such as cancer, infections and autoimmune diseases. The use of this treatment is due to its ability to bolster the immune system’s capacity to identify and destroy cancer cells, offering more effective results and lesser side effects compared to traditional treatments. In the case of HER2-positive breast cancer, immunotherapy enhances the immune system’s ability to identify and confront HER2-overexpressing cancer cells, thus improving treatment results and reducing chances of relapses. To illustrate, the American Association for Cancer Research has reported that by July 2023, there will have been 11 immune checkpoint inhibitors (ICIs) approved by the FDA, with at least one ICI sanctioned for the treatment in 20 different cancer classes and any solid tumor displaying specific molecular traits. Thus, the significant reliance on immunotherapy is prompting the advancement of the HER2-positive breast cancer market.

Which Segments in the HER2-Positive Breast Cancer Offer the Most Growth?

The HER2-positive breast cancer market covered in this report is segmented –

1) By Treatment Type: Targeted Therapy, Chemotherapy, Endocrine Therapy, Immunotherapy, Other Treatment Types

2) By Route Of Administration: Parenteral, Oral, Other Route Of Administrations

3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy

4) By End User: Hospitals, Homecare, Specialty Clinics, Other End User

Subsegments:

1) By Targeted Therapy: HER2 Inhibitors (Trastuzumab, Pertuzumab), Tyrosine Kinase Inhibitors (TKIs), Antibody-Drug Conjugates (ADC), Small Molecule Inhibitors

2) By Chemotherapy: Anthracycline-based Chemotherapy, Taxane-based Chemotherapy, Platinum-based Chemotherapy, Combination Chemotherapy Regimens

3) By Endocrine Therapy: Selective Estrogen Receptor Modulators (SERMs), Aromatase Inhibitors, Estrogen Receptor Antagonists, Estrogen Deprivation Therapy

4) By Immunotherapy: Immune Checkpoint Inhibitors (PD-1/PD-L1 Inhibitors), Monoclonal Antibodies for Immune Modulation, Cancer Vaccines

5) By Other Treatment Types: Radiation Therapy, Stem Cell Therapy, Hyperthermia Treatment, Gene Therapy, Surgical Interventions (Mastectomy, Breast Conserving Surgery)

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=20832&type=smp

What Are the Fastest-Growing Geographies in the HER2-Positive Breast Cancer Market?

North America was the largest region in the HER2- positive breast cancer market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the HER2-positive breast cancer market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What Key Trends Are Shaping the Future of the HER2-Positive Breast Cancer Market?

Leading businesses in the HER2-positive breast cancer market are concentrating their efforts on the creation of advanced therapies such as HER2-focused antibody-drug conjugates (ADCs). These are aimed at improving and streamlining the treatment procedures for patients. HER2-focused ADCs function as targeted cancer treatments, associating a HER2-specific antibody with a cytotoxic drug, which then enables the precise delivery of the drug to HER2-positive cancer cells, enhancing their effective treatment. An example of this innovation is the introduction of Trastuzumab deruxtecan in January 2024 by AstraZeneca India Pharma Ltd., an Indian biopharmaceutical firm. The therapy, which is another form of HER2-focused ADC, was co-developed by AstraZeneca and Daiichi Sankyo and aims to deliver a cytotoxic drug straight to the HER2-positive cancer cells, providing a more focused and productive treatment option for patients.

View the full report here:

https://www.thebusinessresearchcompany.com/report/her2-positive-breast-cancer-global-market-report

What Are the Key Elements That Define the HER2-Positive Breast Cancer Market?

HER2-positive breast cancer refers to a type of breast cancer characterized by the overexpression of the human epidermal growth factor receptor 2 (HER2) protein. This protein promotes the growth of cancer cells and is found in approximately 15-20% of breast cancers. HER2-positive breast cancer is generally more aggressive than HER2-negative forms but is treatable with targeted therapies that inhibit HER2 activity.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20832

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model